BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Our BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, our technology drives the selection and development of new drug candidates. We leverage our BioMAP® Systems technology in collaborations to enhance the productivity of our pharmaceutical partners' pipelines to identify promising compounds for therapeutic development.
Asterand (LON:ATD) shares were lifted by news that its subsidiary BioSeek has renewed its collaboration with Germany’s Merck KgaA.
At 9.04 am, Asterand was trading at 5.125 pence, up 7.8 per cent from yesterday’s close.
BioSeek applies its proprietary BioMAP platform to predict drug responses in pre-clinical models.
It has now signed a new, three-year collaboration agreement with Merck Serono, which expands the previous three-year agreement from 2009.
Under the new research plan, BioSeek will expand the use of BioMAP to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection and nomination of candidates for preclinical development at Merck Serono.
BioMAP Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology.
Asterand put itself up for sale in October and is currently in advanced talks with a small number of preferred parties.